Investment to develop pain therapy
A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative pain therapy.
Spinifex Pharmaceuticals, an emerging biotechnology company specialising in the development of therapeutics for the treatment of neuropathic pain, has attracted investment from a syndicate including Symbiosis Group Limited, Melbourne-based GBS Venture Partners Limited and Uniseed.
Spinifex's core technology relates to the discovery (made by University of Queensland researchers led by Professor Maree Smith) of a novel pathway for the treatment of neuropathic pain. Professor Smith's group successfully validated this pathway using small molecules in well-defined animal models of neuropathic pain.
Colon cancer DNA in blood can guide chemo decisions
A simple blood test could change how doctors decide which patients with colon cancer need...
Non-invasive blood test helps rule out oesophageal cancer
Designed and developed in Australia, the PromarkerEso test is designed to offer a quick,...
Taste-based flu test enables rapid diagnosis
The diagnostic tool consists of the sensor molecule thymol and a virus-specific sugar building...
